Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma 10.1016/j.canlet.2011.12.035 : Cancer Letters | ScienceDirect.com
Abstract
The
adhesion molecule L1CAM (CD171) accounts for enhanced motility,
invasiveness and chemoresistance of tumor cells and represents a novel
marker for various tumor entities including pancreatic and ovarian
carcinoma. Recently, we showed that L1CAM inhibition increases the
apoptotic response of tumor cells towards cytostatic drugs pointing to
the potential of L1CAM to serve as a chemosensitizer in anti-cancer
therapy. Thus, the present study evaluated the therapeutic potential of
combined treatment with L1CAM antibodies and chemotherapeutic drugs in
pancreatic and ovarian carcinoma model systems in vivo.
